Other languages Kura Oncology, Inc.

Equities

KURA

US50127T1097

Real-time Estimate Cboe BZX Other stock markets 10:30:55 2024-04-19 am EDT			5-day change	1st Jan Change
17.58 ^USD	-0.54%		-10.16%	+21.70%

Mar. 14	Transcript : Kura Oncology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM
Mar. 06	Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	Mar. 06
Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	Feb. 26
Kura Oncology Says Study of Leukemia Combination Therapy Yields Positive Early Data	Jan. 30
Top Premarket Gainers	Jan. 30
Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia	Jan. 30
Kura Oncology Expects to Raise $150 Million in Gross Proceeds From Oversubscribed Private Placement	Jan. 24
Top Premarket Gainers	Jan. 24
Sector Update: Health Care Stocks Lean Lower Premarket Friday	Dec. 08
Kura Oncology, The Leukemia & Lymphoma Society to Assess Ziftomenib With Chemotherapy in Children	Dec. 08
Kura Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Sector Update: Health Care Stocks Rising Late Afternoon	Nov. 02
Sector Update: Health Care Stocks Stronger Thursday Afternoon	Nov. 02
Kura Oncology, Mirati Therapeutics Launch Collaboration, Supply Deal to Assess KO-2806, Adagrasib to Treat Lung Cancer	Nov. 02
Kura Oncology, Inc. and Mirati Therapeutics, Inc. Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASG12C-Mutated NSCLC	Nov. 02
Kura Oncology, Inc. Announces First Patient Dosed in Fit-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806	23-10-19
Kura Oncology Says Tipifarnib Shows Overall Response Rate of 30%, 20% in Assessments for Squamous Cell Carcinoma	23-10-17
Kura Oncology Says Lung Cancer Combination Therapy Showed Anti-tumor Activity in Preclinical Trial	23-09-28
Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASG12C Inhibitors in Non-Small Cell Lung Cancer	23-09-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kura Oncology, Inc.

Equities

KURA

US50127T1097

Other languages

Filters